<!DOCTYPE html>
<html lang="en-us"
  dir="ltr">

<head>
  <meta charset="utf-8">
<meta name="viewport" content="width=device-width">



<link rel="icon" type="image/ico" href="https://reports.muthu.co/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://reports.muthu.co/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://reports.muthu.co/favicon-32x32.png">
<link rel="icon" type="image/png" sizes="192x192" href="https://reports.muthu.co/android-chrome-192x192.png">
<link rel="apple-touch-icon" sizes="180x180" href="https://reports.muthu.co/apple-touch-icon.png">

<meta name="description" content=""/>



<title>
    
    Dr Reddys Laboratories Ltd - Jan 2025 Earnings Call Transcript Analysis | Financial Report Insights
    
</title>
<link href="/pagefind/pagefind-ui.css" rel="stylesheet">
<script src="/pagefind/pagefind-ui.js"></script>
<link rel="canonical" href="https://reports.muthu.co/posts/dr-reddys-laboratories-ltd---jan-2025-earnings-call-transcript-analysis/"/>

<meta property="og:url" content="https://reports.muthu.co/posts/dr-reddys-laboratories-ltd---jan-2025-earnings-call-transcript-analysis/">
  <meta property="og:site_name" content="Financial Report Insights">
  <meta property="og:title" content="Dr Reddys Laboratories Ltd - Jan 2025 Earnings Call Transcript Analysis">
  <meta property="og:description" content="Earnings Call Transcript Analysis Report # Financial Performance # Key Financial Metrics:
Consolidated Revenues: Rs. 8,359 crores ($977 million), up 16% YoY and 4% QoQ. Includes Rs. 605 crores from acquired Nicotine Replacement Therapy (NRT) business. Excluding NRT, underlying revenue growth was 7.5% YoY and a decline of 3% QoQ. Consolidated Gross Profit Margin: ~59% (up 19 bps YoY, down 91 bps QoQ). Global Generics Gross Margin: 61.3% PSAI Gross Margin: 28.6% SG&amp;A Spend: Rs. 2,412 crores ($282 million), up 19% YoY and 5% QoQ. As % to sales: 28.9%. R&amp;D Spend: Rs. 666 crores ($78 million), up 20% YoY, down 8% QoQ. As % to sales: 8.0%. Guidance: Expected to be in the range of 8.5-9% for the full fiscal year. EBITDA (including other income): Rs. 2,298 crores ($269 million), up 9% YoY, flat QoQ. EBITDA Margin: 27.5% (down 176 bps YoY, down 95 bps QoQ). Profit Before Tax (PBT): Rs. 1,874 crores ($219 million). PBT as % of revenues: 22.4%. Includes PBT from NRT business of Rs. 124 crores (this excludes interest allocation, only includes amortization). Effective Tax Rate (ETR): 25.1%. Guidance: Normalized ETR expected around 25%. Profit After Tax (PAT attributable to equity holders): Rs. 1,413 crores ($165 million), up 2% YoY, up 13% QoQ. As % of revenues: 17%. Reported EPS: Rs. 16.94 (post stock split and NCI). Operating Working Capital: Rs. 12,782 crores ($1.49 billion). Capex Cash Outflow: Rs. 709 crores ($83 million). Net Cash Surplus: Rs. 1,603 crores ($187 million). Comparisons &amp; Trends:">
  <meta property="og:locale" content="en_us">
  <meta property="og:type" content="article">
    <meta property="article:section" content="posts">
    <meta property="article:published_time" content="2025-01-29T20:27:00+00:00">
    <meta property="article:modified_time" content="2025-01-29T20:27:00+00:00">
    <meta property="article:tag" content="Dr. Reddy&#39;s Laboratories Ltd.">
    <meta property="article:tag" content="DRREDDY">
    <meta property="article:tag" content="Branded Medicines">
    <meta property="article:tag" content="Healthcare">
    <meta property="article:tag" content="Large Cap">
    <meta property="article:tag" content="Earnings Call">













<link rel="stylesheet" href="/assets/combined.min.722a154090e948dfc0b4cf97263194700c53c73fc095c249b60a5c9caddbbf84.css" media="all">




      <script async src="https://www.googletagmanager.com/gtag/js?id=G-T7PH4WNH24"></script>
      <script>
        var doNotTrack = false;
        if ( false ) {
          var dnt = (navigator.doNotTrack || window.doNotTrack || navigator.msDoNotTrack);
          var doNotTrack = (dnt == "1" || dnt == "yes");
        }
        if (!doNotTrack) {
          window.dataLayer = window.dataLayer || [];
          function gtag(){dataLayer.push(arguments);}
          gtag('js', new Date());
          gtag('config', 'G-T7PH4WNH24');
        }
      </script>




<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-3609399560636561" crossorigin="anonymous"></script>
</head>







<body class="light">
  <div class="content">
    <header>
      

<div class="header">

    
    <div id="search"></div>
</div>

    </header>
    <main class="main">
      





<div class="breadcrumbs">
    
    <a href="/">Home</a>
    <span class="breadcrumbs-separator"> > </span>
    
    <a href="/posts/">Posts</a>
    <span class="breadcrumbs-separator"> > </span>
    
    <a class="breadcrumbs-current" href="/posts/dr-reddys-laboratories-ltd---jan-2025-earnings-call-transcript-analysis/">Dr Reddys Laboratories Ltd - Jan 2025 Earnings Call Transcript Analysis</a>
</div>



<div >

  <div class="single-intro-container">

    

    <h1 class="single-title" data-pagefind-body>Dr Reddys Laboratories Ltd - Jan 2025 Earnings Call Transcript Analysis</h1>
    

    

    <p class="single-readtime">
      
      
      
      <time datetime="2025-01-29T20:27:00&#43;00:00">January 29, 2025</time>
      

      
      &nbsp; · &nbsp;
      3 min read
      
    </p>

  </div>

  

  
  

  <div class="single-tags">
    
    <span>
      <a href="https://reports.muthu.co/tags/dr.-reddys-laboratories-ltd./">#Dr. Reddy&#39;s Laboratories Ltd.</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/drreddy/">#DRREDDY</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/branded-medicines/">#Branded Medicines</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/healthcare/">#Healthcare</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/large-cap/">#Large Cap</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/earnings-call/">#Earnings Call</a>
    </span>
    
    
  </div>

  
  

  

  
  <aside class="toc">
    <p><strong>Table of contents</strong></p>
    <nav id="TableOfContents">
  <ul>
    <li><a href="#earnings-call-transcript-analysis-report">Earnings Call Transcript Analysis Report</a></li>
    <li><a href="#financial-performance">Financial Performance</a></li>
    <li><a href="#strategic-initiatives--business-updates">Strategic Initiatives &amp; Business Updates</a></li>
  </ul>
</nav>
  </aside>
  

  

  <div class="single-content">
    <h2 class="heading" id="earnings-call-transcript-analysis-report">
  Earnings Call Transcript Analysis Report
  <a class="anchor" href="#earnings-call-transcript-analysis-report">#</a>
</h2>
<h2 class="heading" id="financial-performance">
  Financial Performance
  <a class="anchor" href="#financial-performance">#</a>
</h2>
<p><strong>Key Financial Metrics:</strong></p>
<ul>
<li><strong>Consolidated Revenues:</strong> Rs. 8,359 crores ($977 million), up 16% YoY and 4% QoQ.
<ul>
<li>Includes Rs. 605 crores from acquired Nicotine Replacement Therapy (NRT) business.</li>
<li>Excluding NRT, underlying revenue growth was 7.5% YoY and a decline of 3% QoQ.</li>
</ul>
</li>
<li><strong>Consolidated Gross Profit Margin:</strong> ~59% (up 19 bps YoY, down 91 bps QoQ).
<ul>
<li>Global Generics Gross Margin: 61.3%</li>
<li>PSAI Gross Margin: 28.6%</li>
</ul>
</li>
<li><strong>SG&amp;A Spend:</strong> Rs. 2,412 crores ($282 million), up 19% YoY and 5% QoQ. As % to sales: 28.9%.</li>
<li><strong>R&amp;D Spend:</strong> Rs. 666 crores ($78 million), up 20% YoY, down 8% QoQ. As % to sales: 8.0%.
<ul>
<li>Guidance: Expected to be in the range of 8.5-9% for the full fiscal year.</li>
</ul>
</li>
<li><strong>EBITDA (including other income):</strong> Rs. 2,298 crores ($269 million), up 9% YoY, flat QoQ.
<ul>
<li>EBITDA Margin: 27.5% (down 176 bps YoY, down 95 bps QoQ).</li>
</ul>
</li>
<li><strong>Profit Before Tax (PBT):</strong> Rs. 1,874 crores ($219 million). PBT as % of revenues: 22.4%.
<ul>
<li>Includes PBT from NRT business of Rs. 124 crores (this excludes interest allocation, only includes amortization).</li>
</ul>
</li>
<li><strong>Effective Tax Rate (ETR):</strong> 25.1%.
<ul>
<li>Guidance: Normalized ETR expected around 25%.</li>
</ul>
</li>
<li><strong>Profit After Tax (PAT attributable to equity holders):</strong> Rs. 1,413 crores ($165 million), up 2% YoY, up 13% QoQ. As % of revenues: 17%.</li>
<li><strong>Reported EPS:</strong> Rs. 16.94 (post stock split and NCI).</li>
<li><strong>Operating Working Capital:</strong> Rs. 12,782 crores ($1.49 billion).</li>
<li><strong>Capex Cash Outflow:</strong> Rs. 709 crores ($83 million).</li>
<li><strong>Net Cash Surplus:</strong> Rs. 1,603 crores ($187 million).</li>
</ul>
<p><strong>Comparisons &amp; Trends:</strong></p>
<ul>
<li>The company delivered its &ldquo;highest ever quarterly revenues and EBITDA in Q3FY25,&rdquo; largely driven by the first-time consolidation of the NRT business.</li>
<li>YoY revenue growth was strong at 16%, but underlying growth (ex-NRT) was a more modest 7.5%.</li>
<li>Sequential revenue decline (ex-NRT) of 3% was noted, partly due to lower sales from products like Lenalidomide in North America.</li>
<li>Gross margin improved YoY due to product mix and manufacturing leverage, offset by price erosion. Sequentially, it declined.</li>
<li>SG&amp;A increased due to NRT business consolidation, investments in new initiatives, and higher logistics costs.</li>
<li>R&amp;D investments continued to focus on complex generics and biosimilars.</li>
<li>EBITDA margin saw a YoY and QoQ decline.</li>
</ul>
<h2 class="heading" id="strategic-initiatives--business-updates">
  Strategic Initiatives &amp; Business Updates
  <a class="anchor" href="#strategic-initiatives--business-updates">#</a>
</h2>
<p><strong>Major Strategic Announcements &amp; Focus:</strong></p>
<ul>
<li>Continued commitment to strengthening core generics and investing in future growth drivers: consumer healthcare (NRT), access to innovative products, and biosimilars.</li>
<li>Focus on R&amp;D productivity, scaling manufacturing and commercial capabilities, and leveraging market access.</li>
</ul>
<p><strong>New Products, Services, or Markets:</strong></p>
<ul>
<li><strong>NRT Business:</strong> First quarter of consolidation. Integration to occur in a phased manner starting April 2025. Seller (Haleon) to provide distribution services during transition.</li>
<li><strong>India Launches:</strong>
<ul>
<li>Toripalimab: First immuno-oncology drug for nasopharyngeal carcinoma.</li>
<li>Elobixibat (BixiBat®): First-in-class drug for chronic constipation.</li>
<li>Six new brands launched in Q3.</li>
</ul>
</li>
<li><strong>Biosimilars Progress:</strong>
<ul>
<li>Rituximab: Marketing Authorization secured in the UK.</li>
<li>Denosumab: Filed in both US and Europe.</li>
</ul>
</li>
<li><strong>Global Generic Launches:</strong>
<ul>
<li>North America: 4 new products in Q3; 15-20 planned for the full year.</li>
<li>Europe: 9</li>
</ul>
</li>
</ul>



<div class="button-container">    
    <a href="https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f3952716-6a60-4a37-8a11-ddfd6c456602.pdf" target="_blank" class="report-button">
      <i class="fas fa-file-pdf"></i> Download Transcript
    </a>
</div>
    



    
  </div>

  


  

  
  

<div class="single-pagination">
    <hr />

    <div class="flex">

        <div class="single-pagination-prev">
            
            <div class="single-pagination-container-prev">
                <div class="single-pagination-text">←</div>
                <div class="single-pagination-text">
                    <a href="/posts/hdfc-bank-ltd---jan-2025-earnings-call-transcript-analysis/">
                        HDFC Bank Ltd - Jan 2025 Earnings Call Transcript Analysis
                    </a>
                </div>
            </div>
            
        </div>

        <div class="single-pagination-next">
            
            <div class="single-pagination-container-next">
                <div class="single-pagination-text">
                    <a href="/posts/polycab-india-ltd---jan-2025-earnings-call-transcript-analysis/">
                        Polycab India Ltd - Jan 2025 Earnings Call Transcript Analysis
                    </a>
                </div>
                <div class="single-pagination-text">→</div>
            </div>
            
        </div>

    </div>

    <hr />
</div>



  <div id="disqus_thread"></div>
<script>
    

    

    (function() { 
    var d = document, s = d.createElement('script');
    s.src = 'https://muthuai.disqus.com/embed.js';
    s.setAttribute('data-timestamp', +new Date());
    (d.head || d.body).appendChild(s);
    })();
</script>
<noscript>Please enable JavaScript to view the <a href="https://disqus.com/?ref_noscript">comments powered by Disqus.</a></noscript>
  

  

  
  <div class="back-to-top">
    <a href="#top">
      back to top
    </a>
  </div>
  

</div>


    </main>
  </div>

  <footer>
    

    
    
    
    <p>Made with ♥ in India</p>
    


  </footer>

  

</body>

<script>

  function isAuto() {
    return document.body.classList.contains("auto");
  }

  function setTheme() {
    if (!isAuto()) {
      return
    }

    document.body.classList.remove("auto");
    let cls = "light";
    if (window.matchMedia && window.matchMedia('(prefers-color-scheme: dark)').matches) {
      cls = "dark";
    }

    document.body.classList.add(cls);
  }

  function invertBody() {
    document.body.classList.toggle("dark");
    document.body.classList.toggle("light");
  }

  if (isAuto()) {
    window.matchMedia('(prefers-color-scheme: dark)').addListener(invertBody);
  }

  setTheme();

</script>
<script>
    window.addEventListener('DOMContentLoaded', (event) => {
        new PagefindUI({ element: "#search", showSubResults: false, showImages: false });
    });
</script>
<script defer src="/js/copy-code.js"></script>
</html>